Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunotherapy in hepatobiliary tumors: search for the missing pieces of the puzzle.

Literature DB >> 32142066

Immunotherapy in hepatobiliary tumors: search for the missing pieces of the puzzle.

Matteo Donadon^1,2, Federica Marchesi^3,4, Lorenza Rimassa^2,5, Guido Torzilli^1,2.

Abstract

Entities: Chemical

Year: 2020 PMID： 32142066 PMCID： PMC7026800 DOI： 10.21037/hbsn.2019.10.33

Source DB: PubMed Journal: Hepatobiliary Surg Nutr ISSN： 2304-3881 Impact factor: 7.293

× No keyword cloud information.

11 in total

Review 1. The yin and yang of evasion and immune activation in HCC.

Authors: Oxana V Makarova-Rusher; José Medina-Echeverz; Austin G Duffy; Tim F Greten
Journal: J Hepatol Date: 2015-02-27 Impact factor: 25.083

2. Shaping the landscape of immune oncology in hepatocellular carcinoma.

Authors: Nicola Personeni; Lorenza Rimassa
Journal: Lancet Oncol Date: 2018-06-03 Impact factor: 41.316

3. Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery.

Authors: Luca Vigano; Cristiana Soldani; Barbara Franceschini; Matteo Cimino; Ana Lleo; Matteo Donadon; Massimo Roncalli; Alessio Aghemo; Luca Di Tommaso; Guido Torzilli
Journal: J Gastrointest Surg Date: 2019-01-31 Impact factor: 3.452

4. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Authors: Andrew X Zhu; Richard S Finn; Julien Edeline; Stephane Cattan; Sadahisa Ogasawara; Daniel Palmer; Chris Verslype; Vittorina Zagonel; Laetitia Fartoux; Arndt Vogel; Debashis Sarker; Gontran Verset; Stephen L Chan; Jennifer Knox; Bruno Daniele; Andrea L Webber; Scot W Ebbinghaus; Junshui Ma; Abby B Siegel; Ann-Lii Cheng; Masatoshi Kudo
Journal: Lancet Oncol Date: 2018-06-03 Impact factor: 41.316

Review 5. Implications of Immunotherapy in Hepatobiliary Tumors.

Authors: Aline Gottlieb; Jan Best; Ali Canbay
Journal: Visc Med Date: 2019-02-08

6. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.

Authors: Lynn G Feun; Ying-Ying Li; Chunjing Wu; Medhi Wangpaichitr; Patricia D Jones; Stephen P Richman; Beatrice Madrazo; Deukwoo Kwon; Monica Garcia-Buitrago; Paul Martin; Peter J Hosein; Niramol Savaraj
Journal: Cancer Date: 2019-06-28 Impact factor: 6.860

Review 7. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.

Authors: Lorenza Rimassa; Nicola Personeni; Alessio Aghemo; Ana Lleo
Journal: J Autoimmun Date: 2019-03-09 Impact factor: 7.094

8. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors: Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal: Lancet Date: 2017-04-20 Impact factor: 79.321